There’s been a growing interest in this product ever since it was introduced. And it’s no wonder. LATISSE® is the first FDA-approved prescription treatment for inadequate or not enough eyelashes, growing them longer, fuller and darker.
Discover the LATISSE® difference.
LATISSE® solution is a growth treatment for hypotrichosis (inadequate or not enough eyelashes). In fact, it’s the first FDA-approved treatment clinically proven to grow lashes. And it’s the first lash growth product of its kind available by prescription. So you’ll need to talk to your doctor to see if it’s right for you.
LATISSE® grows lashes longer, fuller and darker.
LATISSE® solution is a once-nightly treatment you apply topically to the base of your upper eyelashes, as instructed by your doctor. Then, gradually, the results come in. You may start to see more length in as little as 4 weeks and you should achieve full growth in 16 weeks. It’s not an illusion of growth. It’s real lash growth.
How LATISSE® works.
LATISSE® makes lash growth possible because of its active ingredient: bimatoprost. Although the precise mechanism of action is unknown, LATISSE® is believed to affect the growth (anagen) phase of the eyelash hair cycle in two ways: first, it increases the length of this phase, and second, it increases the number of hairs in this growth phase.
The history behind LATISSE®.
LATISSE® was created by Allergan. In 2001, Allergan developed a medicated eye drop to treat elevated intraocular pressure. Many patients using this medication also began to grow longer, fuller and darker lashes as a side effect. This led Allergan to study the medication's active ingredient, bimatoprost, specifically for growing lashes. After a clinical trial, LATISSE® was approved by the FDA in December of 2008.
LATISSE® (bimatoprost ophthalmic solution) 0.03% Important Information
Indication
LATISSE® (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length, thickness, and darkness.
Important Safety Information
Contraindications: LATISSE® is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients.
Warnings and Precautions: In patients using LUMIGAN® (bimatoprost ophthalmic solution) or other prostaglandin analogs for the treatment of elevated intraocular pressure (IOP), the concomitant use of LATISSE® may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including LUMIGAN® for IOP reduction should only use LATISSE® after consulting with their physician and should be monitored for changes to their intraocular pressure.
Increased iris pigmentation has occurred when bimatoprost solution was administered. Patients should be advised about the potential for increased brown iris pigmentation, which is likely to be permanent.
Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes.
There is the potential for hair growth to occur in areas where LATISSE® solution comes in repeated contact with skin surfaces. Apply LATISSE® only to the skin of the upper eyelid margin at the base of the eyelashes.
LATISSE® solution should be used with caution in patients with active intraocular inflammation (eg, uveitis) because the inflammation may be exacerbated. LATISSE® should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.
Adverse Reactions: The most frequently reported adverse reactions were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and periorbital erythema. These reactions occurred in less than 4% of patients.
Postmarketing Experience: The following adverse reactions have been identified during postapproval use of LATISSE®: dry skin of the eyelid and/or periocular area, eye swelling, eyelid edema, hypersensitivity (local allergic reactions), lacrimation increased, madarosis and trichorrhexis (temporary loss of a few eyelashes to loss of sections of eyelashes, and temporary eyelash breakage, respectively), periorbital and lid changes associated with a deepening of the eyelid sulcus, rash (including macular and erythematous), skin discoloration (periorbital), and vision blurred.
For more information on LATISSE®, please see the accompanying full Prescribing Information.
LAT109784 08/17